Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival

Clinical Cancer Research

Volumn 2, Issue 6, 1996, Pages 1063-1066

  Fisch, Michael J ^a,b   Howard, Kelly L ^a   Einhorn, Lawrence H ^a   Sledge, George W ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b Richard L Roudeboush Vet Aff M   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; CISPLATIN; PLATINUM;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DNA DRUG COMPLEX; GERM CELL TUMOR; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CISPLATIN; DNA ADDUCTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GERMINOMA; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; PLATINUM; PROSPECTIVE STUDIES; TESTICULAR NEOPLASMS;

EID: 0029974336     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Einhorn, L. H. Treatment of testicular cancer: a new and improved model. J. Clin. Oncol., 8: 1777-1781, 1990
2. Motzer, R. J., Bajorin, D. F., and Bosl, G. J. "Poor-risk" germ cell tumors: current prognosis and future directions. Semin. Oncol., 19: 206-214, 1992.
3. Poirer, M. C., Reed, E., Shamkhani, H., Tarone, R. E., and Gupta-Burt, S. Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy. Environ. Health Perspect., 99: 149-154, 1993.
4. Johnson, S. W., Perez, R. P., Godwin, A. K., Yeung, A. T., Handel, L. M., Ozols, R. F., and Hamilton, T. C. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem. Pharmacol., 47: 689-697, 1994
5. Johnson, S. W., Swiggard, P. A., Handel, L. M., Brennan, J. M., Godwin, A. K., Ozols, R. F., and Hamilton, T. C. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells. Cancer Res., 54. 5911-5916, 1994.
6. Motzer, R. J., Reed, E., Perera, F., Tang, D., Shamkhani, H., Poirer, M. C., Tsai, W., Parker, R. J., and Bosl, G. J. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Cancer (Phila.), 73: 2843-2852, 1994.
7. Poirer, M. C. DNA adduces induced by platinum drug chemotherapeutic agents in human tissues. Prog. Clin. Biol. Res., 374: 197-212, 1992.
8. Reed, E., Ozols, R. F., Tarone, R., Yuspa, S. H., and Poirer, M. C. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy Proc. Natl. Acad. Sci. USA, 84: 5024-5028, 1987.
9. Reed, E., Ozols, R. F., Tarone, R., Yuspa, S. H., and Poirer, M. C. The measurement of cisplatin-DNA adduct levels in testicular cancer patients. Carcinogenesis (Lond.), 9: 1909-1911, 1988.
10. Reed, E., Ostchega, Y., Steinberg, S. M., Yuspa, S. H., Young, R. C., Ozols, R. F., and Poirer, M. C. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res., 50: 2256-2260, 1990.
11. Reed, E., Parker, R. J , Gill, I., Bicher, A., Meenakshi, D., Vionnet, J. A., Bostick-Bruton, F., Tarone, R., and Muggia, F. M. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res., 53: 3694-3699, 1993.
12. Birch, R., Williams, S., Cone, A., Einhorn, L., Roark, P., Turner, S., and Greco, F. Prognostic factors for favorable outcome in disseminated germ cell tumors. J. Clin. Oncol., 4: 400-407, 1986.
13. Loehrer, P., Lauer, R., Roth, B., Williams, S., Kalasinski, L., and Einhorn, L. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann. Intern. Med., 109: 540-546, 1988.
14. Williams, S., Birch, R., Einhorn, L., Irwin, L., Greco, F., and Loehrer, P. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med., 316: 1435-1440, 1987.
15. Blanke, C., Loehrer, P., Einhorn, L., and Nichols, C. A phase II study of VP-16 plus ifosfamide plus cisplatin plus vinblastine plus bleomycin (VIP/VB) with filgrastim for advanced stage testicular cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 13: 234, 1994.
16. Loehrer, P. J., Einhorn, L. H., Elson, P., Williams, S. D., Havlin, K., Vogelzang, N. J., Crawford, E. D., and Trump, D. L Phase III study of cisplatin plus etoposide with either bleomycin or ifosfamide in advanced stage germ cell tumors. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 12: 261, 1993.
17. Reed, E., Sauerhoff, S., and Poirer, M. C. Quantitation of platinum-DNA binding after therapeutic levels of drug exposure: a novel use of graphite furnace spectrometry. Atomic Spectroscopy, 9: 93-95, 1988.